Parkinson's Disease clinical trials
Showing 101–150 of 314 active trials. Describe your situation to see which ones look like a fit.
- Daily Amino Acid Supplementation for People With Parkinson's Disease
- Remote Haptic Rehabilitation for Parkinson's Disease
- Steady Together Fall Prevention Program in the Home
- Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
- Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)
- A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
- Blood Pressure Effects on Cognition and Brain Blood Flow in PD
- The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- Real-Time Levodopa Level Monitoring in Parkinson Disease
- Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)
- Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
- Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
- Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
- Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
- 18F-mFBG Cardiac Uptake With Lewy Body Dementia
- CW2IP2: Imaging and Diagnostic Assessments
- Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia
- PET Tau - Neurodegenerative Disease Imaging
- Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
- PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
- Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS
- A Novel Digital Music-based Autonomous Personalized Walking Intervention to Improve Gait and Walking Automaticity in Parkinson Disease
- Superior Parietal iTBS for PD-MCI
- Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation
- Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
- Sensing in Sleep Deep Brain Stimulation
- A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications
- Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
- Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder
- Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
- Neuroimaging of Parkinson's
- Cognitive Decline Following Deep Brain Stimulation: A DBS-fMRI Study
- Optimizing Deep Brain Stimulation to Improve Visuomotor Function in Parkinson's Disease
- Black and African Americans Connections to Parkinson's Disease (BLAAC PD)
- Home-Based Monitoring in Parkinson's Disease
- Pathways Mediating Impaired Postural Control in Parkinson's Disease
- Kinematic and Neural Dynamics of Postural Instability in Parkinson's Disease
- Social & QoL Behaviors in Parkinson's Disease
- Adaptive DBS to Offset STN Dysregulation During Exercise in PD
- Cognitive Decline Following Deep Brain Stimulation
- Udall Project 2 Aim 2A&C
- Circuit-Based Deep Brain Stimulation for Parkinson's Disease P1A2&3 Catalyst
- Udall Project 1 Aim 4
- A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
- Sensory Filtering in the Human Basal Ganglia as a Mechanism of Parkinson's Disease
- Deep Brain Stimulation for Visuomotor Function in Parkinson's Disease
- Naturalistic Sleep Assessed by Wearable Devices in Parkinson Disease
- Parkinson Progression Marker Initiative Online (PPMI Online)
- Parkinson's Foundation Surveys
- Parkinson's Foundation PD GENEration Genetic Registry
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.